Corneal thickness and endothelial changes in long-term hydroxychloroquine use

Oğurel, Tevfik; Özer, Murat Atabey; Akbulut, Yaprak; Gökçinar, Nesrin Büyüktortop; Onaran, Zafer; Üreten, Kemal

doi:10.1080/15569527.2019.1608228

Cited by 6 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In most cases, corneal deposits are reversible on drug discontinuation [18]. In addition, previous studies have reported decreased corneal endothelial cell density, increased central corneal thickness, and other changes in corneal parameters in patients with long-term HCQ use [24][25][26]. Our results also showed decreased corneal endothelial cell density and increased central corneal thickness in the HCQ treatment group, although they were not statistically significant.…”

Section: Discussioncontrasting

confidence: 56%

Evaluation of Corneal and Retinal Toxicity in Rheumatoid Arthritis Patients Treated with Hydroxychloroquine

et al. 2022

View full text Add to dashboard Cite

Introduction: To assess the ocular toxicity of hydroxychloroquine (HCQ) by confocal microscopy, multifocal electroretinography (mfERG), and scanning laser polarimetry with variable corneal compensation (GDxVCC) in patients with rheumatoid arthritis (RA). Methods: A cross-sectional, comparative case series study was retrospectively conducted on 61 patients under HCQ treatment for RA without fundoscopic anomalies (Group 1), 65 RA patients with no HCQ treatment (Group 2), and 27 normal subjects (Group 3). A comprehensive ophthalmological examination, including confocal microscopy, mfERG, and GDxVCC, was performed in the three groups. Results: In Group 1, the duration of treatment ranged from 19 to 96 months (54.9 ± 15.2 months). The mean cumulative dose of HCQ was 446.1 ± 164.0 g (range 114 - 864 g). Confocal microscopy revealed hyper-reflective abnormal particles in 45 patients (73.8%) and beaded, tortuous fibres in 34 patients (55.7%) in group 1. No corneal change was observed in the other two groups. The mfERG responses in the 6 concentric rings (R1 - R6) among the three groups differed except at R3 (all P < 0.05), and data from R1 - R6 were not significantly different between Groups 2 and 3. The retinal nerve fibre layer (RNFL) thicknesses were statistically thinner in Group 1 than in Groups 2 and 3 (all P < 0.05). Conclusions: Early signs of corneal and neural retina structure changes were detected in patients with RA treated with hydroxychloroquine. Whether these findings should be a mark of drug recession still needs further study and more evidence.

show abstract

Section: Discussioncontrasting

confidence: 56%

Evaluation of Corneal and Retinal Toxicity in Rheumatoid Arthritis Patients Treated with Hydroxychloroquine

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A hidroxicloroquina (HCQ) é um derivado da 4-aminoquinolina que tem sido muito usado para prevenção da malária por anos; é um agente sintético amplamente utilizado no tratamento de diversas doenças devido a seu efeito anti-inflamatório e também propriedades imunossupressoras 1 . Sendo inserida no mercado por volta de 1955, diferencia-se da cloroquina por um grupo hidroxila que o torna mais seguro, sendo indicado para o tratamento de doenças como artrite reumatoide, lúpus eritematoso sistêmico, discoide e malária 2 .…”

Section: Introductionunclassified

Parâmetros farmacocinéticos, farmacodinâmicos e toxicidade da hidroxicloroquina

De Melo Andrade Júnior,

Machado da Cunha Cavalcanti,

Inacio

et al. 2024

J Health Biol Sci.

View full text Add to dashboard Cite

Objetivo: verificar a toxicidade do uso medicamentoso da hidroxicloroquina em pacientes. Metodologia: trata-se de uma revisão integrativa de literatura com uma avaliação documental e abordagem descritiva nas bases de dados eletrônicos LILACS, SCIELO e MEDLINE-PUBMED, usando diferentes combinações de descritores, publicados entre os anos de 2015 a 2023, nos idiomas inglês, espanhol e português. Resultados: este estudo revisou 117 artigos científicos, dos quais 67 foram nos Estados Unidos. Além disso, o ano de 2020 obteve 21,2% a mais de publicações em relação ao ano de 2015. Desse modo, notou-se que a prevalência de 44,07% das lesões pelo uso da hidroxicloroquina foi oftálmica, 35,5% foram cardíacas, 14,4%, dermatológicas e as outras demais porcentagens restantes. Conclusão: portanto, os resultados obtidos confirmam a toxicidade da hidroxicloroquina no uso de tratamentos adjacentes.

show abstract